Learn about CIBINQO®, a prescription treatment for people 12+ with refractory moderate-to-severe eczema uncontrolled with orals or injectables. See safety info.

Learn more about moderate-to-severe eczema, or atopic dermatitis, including common signs, symptoms, and potential causes. See safety info, risks & benefits.

Cibinqo (abrocitinib) is an oral JAK1 inhibitor approved by the FDA for adults and adolescents aged 12+ years with refractory moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

2023年10月26日 · Cibinqo (abrocitinib) tablets are used to treat eczema (atopic dermatitis) that is moderate to severe in patients who have not found relief with topical medications or are not able to use them. Cibinqo is a once-a-day tablet that can …

Review side effects and safety information for CIBINQO®, a once daily moderate-to-severe eczema prescription treatment for adults and children 12 years of age and older.

Learn about CIBINQO™ for people 12 years and older with refractory moderate-to-severe eczema uncontrolled with other Rx treatments including biologics, or who can't tolerate these therapies.

2024年8月2日 · Cibinqo (abrocitinib) is commonly used to treat a disorder that causes inflammation and irritation of your skin called atopic dermatitis, which is the most common type of eczema. Learn more...

Abrocitinib, also known as Cibinqo ®, is a treatment for moderate to severe atopic eczema (also known as atopic dermatitis) in adults and children aged 12 years and older. It’s a type of drug known as a Janus kinase (JAK) inhibitor. Abrocitinib is taken orally, as a tablet.

Abrocitinib is an effective systemic therapy, easy to administer as an oral medication that can be taken with or without food, and usually well tolerated. In clinical trials, it reduces the severity of atopic eczema with significant clearing of the skin and rapid improvement of itch (pruritus) when compared to placebo.

Cibinqo is approved by the U.S. Food and Drug Administration (FDA) for treating adults and adolescents aged 12 and older with moderate to severe atopic dermatitis (the most common type of eczema) that is not well-managed by other systemic treatments, such as biologics, or when those therapies are not suitable.